1.进入Ⅲ期,礼来GLP-1三靶点新药冲入疼痛赛道近日,ClinicalTrials.gov网站显示,礼来登记了旗下GLP-1/GIP/GCG三靶点激动剂retatrutide在肥胖或超重伴慢性腰痛患者中疗效和安全性的Ⅲ期TRIUMPH-7临床研究。据悉,该试验为随机、双盲、安慰剂对照研究,预计为期80周,计划入组586名患者。Insight数据库显示,在GLP-1三靶点激动剂赛道,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.